Since 1982, Dr. Tanzi has focused his studies on Alzheimer's disease (AD). He isolated the first familial Alzheimer's disease (FAD) gene, known as the amyloid beta-protein (A4) precursor (APP) in 1987, and another in 1995, called presenilin 2. He also collaborated on the isolation of the second FAD gene, presenilin 1.
In 1993, Dr. Tanzi isolated the gene responsible for the neurological disorder known as Wilson's disease, and over the past 25 years, he has collaborated on studies identifying several other neurodegenerative disease genes including those causing amyotrophic lateral sclerosis and neurofibromatosis.
Dr. Tanzi’s laboratory first discovered that the metals zinc and copper are necessary for the formation of neurotoxic assemblies of the AD-associated peptide, A-beta, the main component of beta-amyloid deposits in brains of AD patients. These studies have led to ongoing clinical trials for treating and preventing AD by targeting A-beta metal interactions. Dr. Tanzi was also involved in the first studies implicating gamma-secretase modulators as therapeutics for AD.
Dr. Tanzi is currently carrying out genome wide association screens to identify novel genes associated with AD and autism spectrum disorders. Candidate disease genes are then characterized at the molecular, cell biological, and biochemical levels to elucidate disease mechanisms.
Rudolph E. Tanzi, PhD
Research Assistants & Technicians
Interns & Students
Alzheimer's Disease-Associated Amyloid beta-Protein
A recent study from the Tanzi Lab and collaborators suggests that A-beta is a hitherto unrecognized antimicrobial peptide (AMP) that may normally function in the innate immune system. This finding stands in stark contrast to current models of A-beta-mediated pathology and has important implications for ongoing and future AD treatment strategies.
We have shown that A-beta is active against at least eight common and clinically relevant microorganisms. This photomicrograph (18,500x) shows bacteria being attacked by A-beta, which is forming beta-amyloid fibrils and attaching to other the bacteria in the picture. The fibrils eventually entrap the bacteria and cause them to lyse.
A low magnification electron micrograph of the same experiment shows the result of A-beta added to bacteria (left side), compared with the right side, with no A-beta.
To inquire about research positions, e-mail email@example.com. You will receive an automated reply with instructions. Please do not attach any files.
Leveraging Alzheimer’s Genome Project™ data, geneticist Rudy Tanzi, PhD, completes research to discover all gene variants that increase a person’s risk of Alzheimer’s disease.
On Oct. 18, at a press conference in Cambridge, the Cure Alzheimer’s Fund announced a fitting $5.4 million contribution to the MGH to fund state-of-the-art whole genome DNA sequencing that aims to enhance understanding of the genetic roots of Alzheimer’s.
Public Transportation Access: yes
Disabled Access: yes
How to Apply for Positions
How to apply for jobs: Send an e-mail to firstname.lastname@example.org to receive an automated e-mail with full instructions for all types of positions.
Contact Shawn Fitzgibbons in the Mass General Development office at 617-643-0447 or email@example.com.
Anne B. Young, MD, PhD
Director, Massgeneral Institute for Neurodegenerative Disease
Professor of Neurology, Harvard Medical School
Clinical Appointments, Consultations & Clinical Trials
ALS (Amyotrophic Lateral Sclerosis) Multidisciplinary Clinic
Frontotemporal Disorders Unit
Huntington's Disease Clinic
Memory Disorders Unit
Alzheimers, Dementia with Lewy Bodys, Frontotemporal dementia, Pick's Disease
Movement Disorders Unit
Dystonia, Huntingtons, Parkinsons
Parkinson Disease and Movement Disorders Clinic